103,800 Shares in Bristol Myers Squibb Company $BMY Bought by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System acquired a new position in Bristol Myers Squibb Company (NYSE:BMY) in the 1st quarter, HoldingsChannel.com reports. The firm acquired 103,800 shares of the biopharmaceutical company’s stock, valued at approximately $6,295,000.

A number of other large investors have also recently bought and sold shares of BMY. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at $25,000. Swiss RE Ltd. purchased a new position in shares of Bristol Myers Squibb during the 4th quarter valued at about $25,000. Physician Wealth Advisors Inc. boosted its stake in shares of Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 202 shares during the last quarter. Bayban acquired a new stake in Bristol Myers Squibb during the fourth quarter worth about $31,000. Finally, EQ Wealth Advisors LLC purchased a new position in Bristol Myers Squibb during the fourth quarter valued at approximately $32,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Insider Activity at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares in the company, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Wall Street Zen lowered Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 6th. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. HSBC raised their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research report on Tuesday, March 17th. Weiss Ratings reiterated a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Finally, Guggenheim restated a “buy” rating and set a $72.00 target price on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Bristol Myers Squibb currently has an average rating of “Hold” and a consensus price target of $61.31.

Bristol Myers Squibb Stock Up 0.6%

BMY stock opened at $55.33 on Friday. The stock has a market capitalization of $112.98 billion, a P/E ratio of 15.54, a P/E/G ratio of 0.16 and a beta of 0.24. The firm has a 50-day simple moving average of $57.07 and a 200-day simple moving average of $57.27. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same period last year, the company posted $1.80 EPS. Bristol Myers Squibb’s quarterly revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities analysts forecast that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be paid a $0.63 dividend. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.6%. Bristol Myers Squibb’s payout ratio is currently 70.79%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.